A new trading day began on Tuesday, with Nurix Therapeutics Inc (NASDAQ: NRIX) stock price down -5.70% from the previous day of trading, before settling in for the closing price of $13.34. NRIX’s price has ranged from $11.90 to $29.56 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 24.84% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -12.94%. With a float of $74.38 million, this company’s outstanding shares have now reached $75.87 million.
In an organization with 286 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 77.77%, operating margin of -390.52%, and the pretax margin is -354.36%.
Nurix Therapeutics Inc (NRIX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Nurix Therapeutics Inc is 1.99%, while institutional ownership is 108.22%. The most recent insider transaction that took place on Mar 03 ’25, was worth 84,388. In this transaction Chief Financial Officer of this company sold 5,825 shares at a rate of $14.49, taking the stock ownership to the 33,724 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Officer proposed sale 5,825 for $15.45, making the entire transaction worth $89,996.
Nurix Therapeutics Inc (NRIX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -12.94% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.21% during the next five years compared to -38.86% drop over the previous five years of trading.
Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators
Here are Nurix Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.46. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.89, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach -3.39 in one year’s time.
Technical Analysis of Nurix Therapeutics Inc (NRIX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.26 million. That was better than the volume of 0.78 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 13.68%. Additionally, its Average True Range was 0.90.
During the past 100 days, Nurix Therapeutics Inc’s (NRIX) raw stochastic average was set at 0.24%, which indicates a significant decrease from 1.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.17% in the past 14 days, which was higher than the 59.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.78, while its 200-day Moving Average is $20.81. However, in the short run, Nurix Therapeutics Inc’s stock first resistance to watch stands at $13.23. Second resistance stands at $13.89. The third major resistance level sits at $14.23. If the price goes on to break the first support level at $12.23, it is likely to go to the next support level at $11.89. The third support level lies at $11.23 if the price breaches the second support level.
Nurix Therapeutics Inc (NASDAQ: NRIX) Key Stats
With a market capitalization of 954.66 million, the company has a total of 75,887K Shares Outstanding. Currently, annual sales are 54,550 K while annual income is -193,570 K. The company’s previous quarter sales were 13,280 K while its latest quarter income was -58,550 K.
